Investigation of the effect of curcumin supplementation on clinical status, inflammatory factors, oxidative stress biomarkers in patients with rheumatoid arthritis

Determining the effect of curcumin supplementation on clinical symptoms, inflammatory factors, oxidative stress biomarkers in Rheumatoid arthritis patients

In this clinical trial (phase 3), two parallel, two-blind, randomized groups with two groups as Control and Intervention (30 people in each group) were first selected as available and then randomly selected in each group. They are selected based on body mass index and weight

This study was conducted in Rheumatoid arthritis patients referred to the Rheumatology clinic of Shahid Beheshti Hospital in Kashan. In this study, patients in both Intervention and Control groups receive standard treatment. In the intervention group, Curcumin produced by Dinah Pharmaceutical Company, with a dose of 500 mg, 1 tablet daily for 12 weeks, in addition to standard treatment and in the control group Placebo is used in addition to standard treatment. Placebo and Curcumin are both in the same form, same weight and same packaging, which is written by the researcher on the back of the package, and the doctor and the patient do not know whether it is a drug or a placebo.

Inclusion criteria: Patients with Rheumatoid arthritis based on diagnostic criteria Age 20-70 years No smoking. Exclusion criteria: Reluctance to cooperate Hypothyroidism or hyperthyroidism Consumption of any type of supplement (Vitamins, salts, etc.) by the patient during the last 3 months Having any acute and active infection.

Intervention group: Taking Curcumin alongside standard treatment Control group: receiving a Placebo alongside the standard treatment

Severity of clinical symptoms before and after treatment based on Disease Activity Score 28 and Visual Analog Scale; plasma total antioxidant; plasma malondialdehyde; serum Hs-CRP

In this study, initial sampling is done by the 'available' method from the rheumatology clinic of Beheshti Hospital among the patients who come for treatment. The way of randomization is that rheumatoid arthritis patients are placed in separate classes based on two criteria: BMI (BMI < 30 and BMI ≥ 30) and age (> 45 and ≤ 45) and then are randomly assigned to one of the two groups. Curcumin or placebo (containing starch) are added as supplements. Randomization is done using Stat Trek software and based on the random number table method.

The patient and the attending physician are not aware of the fact that the patient is receiving a placebo or curcumin supplement.